Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid

Risultato della ricerca: Contributo in rivistaArticolo in rivista

1 Citazioni (Scopus)

Abstract

Acute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The discovery of the molecular pathogenesis has led to the first targeted therapy for acute leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based chemotherapy obtaining high response rates, but some potential longterm sequelae are described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to standard chemotherapy in a pivotal trial with excellent results both in terms of complete
Lingua originaleEnglish
pagine (da-a)1330-1338
Numero di pagine9
RivistaLEUKEMIA & LYMPHOMA
Stato di pubblicazionePubblicato - 2019

Keywords

  • transfusion support promyelocytic leukemia

Fingerprint

Entra nei temi di ricerca di 'Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid'. Insieme formano una fingerprint unica.

Cita questo